Dey Ipratropium Reprint Warning Not In Conflict With WLF Ruling, FDA Says
A warning letter issued by FDA regarding implied superiority claims by Dey Labs in a journal reprint disseminated for its generic ipratropium is consistent with the recent Washington Legal Foundation ruling, FDA maintained.
You may also be interested in...
The Washington Legal Foundation will challenge FDA's request for an expedited appeal to D.C. District Court Judge Royce Lamberth's July 28 ruling invalidating the off-label dissemination provisions of the FDA Modernization Act, WLF Chief Counsel Richard Samp told a Food & Drug Law Institute conference in Bethesda, Md. Sept. 13.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials